Аннотация

Бемориҳои тарбодӣ (БТ) — гурӯҳи патологияҳои музмини илтиҳобӣ ва дегенеративии системаи устухону мушакҳо ва бофтаи пайвасткунанда мебошанд, ки аксаран табиати аутоиммунӣ доранд. Онҳо мушкилоти глобалии соҳаи тандурустӣ ба ҳисоб мераванд, зеро яке аз сабабҳои асосии маъюбии доимӣ, пастшавии сифати зиндагӣ ва марги бармаҳал мебошанд. Дар ин шарҳ маълумоти муосири эпидемиологӣ ва механизмҳои асосии иммунопатогенетикӣ, ки фенотипҳои клиникиро муайян мекунанд, таҳлил мегарданд. Ба тағйирёбии пешгӯӣ тавассути стратегияҳои нави терапевтӣ таваҷҷуҳи махсус дода шудааст: принсипи «табобат то ба даст овардани ҳадаф» ва истифодаи доруҳои ҳадафнок — доруҳои биологӣ ва синтетикии асосии зиддиилтиҳобӣ (МАЗИ). Ҷустуҷӯи манбаъҳои адабӣ дар пойгоҳҳои маълумотии PubMed, MEDLINE, Scopus, Web of Science, КиберЛенинка ва eLIBRARY барои солҳои 2018–2025 бо истифода аз калимаҳои калидии зерин анҷом дода шуд: «бемориҳои тарбодӣ», «паҳншавӣ», «патогенез», «иммунология», «табобати биологӣ», «маводҳои асосии зиддиилтиҳобӣ», «табобат то ба даст овардани ҳадаф».
 

Калимаҳои калидӣ

бемориҳои тарбодӣ (БТ) паҳншавӣ иммунопатогенез маводҳои асосии зиддиилтиҳобии (МАЗИ) терапияи биологӣ стратегия «табобат то ба даст овардани ҳадаф».

Матни пурра

Боргирӣ кардани мақола дар PDF

Версияи пурраи мақола дар формати PDF

Феҳристи манбаъ

  1. GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2133–2161. https://doi.org/10.1016/S0140-6736(24)00757-8.
  2. GBD 2021 Other Musculoskeletal Disorders Collaborators. Global, regional, and national burden of other musculoskeletal disorders, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5(11):e670–e682. https://doi.org/10.1016/S2665-9913(23)00232-1.
  3. Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia MA, et al. Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the Global Burden of Disease Study 2017. Ann Rheum Dis. 2019;78(11):1463–1471. https://doi.org/10.1136/annrheumdis-2019-215920.
  4. Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int. 2021;41(5):863–877. https://doi.org/10.1007/s00296-020-04731-0.
  5. Finckh A, Gilbert B, Hodkinson B, Bae SC, Thomas R, Deane KD, et al. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 2022;18(10):591–602. https://doi.org/10.1038/s41584-022-00827-y.
  6. Плахова АО, Сороцкая ВН, Вайсман ДШ, Балабанова РМ. Ревматоидный артрит: распространённость и заболеваемость в разных странах. Современная ревматология. 2025;19(1):7–11. https://doi.org/10.14412/1996-7012-2025-1-7-11
  7. Garrido-Cumbrera M, Poddubnyy D, Gossec L, Gálvez-Ruiz D, Bundy C, Mahapatra R, et al. The European Map of Axial Spondyloarthritis: Capturing the Patient Perspective—an Analysis of 2846 Patients Across 13 Countries. Curr Rheumatol Rep. 2019;21(5):19. https://doi.org/10.1007/s11926-019-0819-8.
  8. Navarro-Compán V, Sepriano A, Capelusnik D, Baraliakos X. Axial spondyloarthritis. Lancet. 2025;405(10473):159–172. https://doi.org/10.1016/S0140-6736(24)02263-3.
  9. Karmacharya P, Chakradhar R, Ogdie A. The epidemiology of psoriatic arthritis: A literature review. Best Pract Res Clin Rheumatol. 2021;35(2):101692. https://doi.org/10.1016/j.berh.2021.101692.
  10. Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023;82(3):351–356. https://doi.org/10.1136/ard-2022-223035.
  11. Hummers LK. Clinical Trials in Systemic Sclerosis: Crossroads and Opportunities. Arthritis Rheumatol. 2023;75(8):1328–1330. https://doi.org/10.1002/art.42514
  12. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16(7):380–390. https://doi.org/10.1038/s41584-020-0441-1.
  13. Шодиев БР, Шукурова СМ, Абдуллаев МФ, Курбонова ФУ. Характеристика сопутствующей патологии при ревматических заболеваниях. Вестник последипломного образования в сфере здравоохранения. 2019;(4):91–97. EDN HUVCEK
  14. Katz J, Bartels CM. Multimorbidity in Rheumatoid Arthritis: Literature Review and Future Directions. Curr Rheumatol Rep. 2024;26(1):24–35. https://doi.org/10.1007/s11926-023-01121-w.
  15. Журавлева ЮА, Гусев ЕЮ. Взаимосвязь системной воспалительной реакции и гиперкоагуляции у пациентов с иммуновоспалительными ревматическими заболеваниями. Медицинская иммунология. 2023;25(5):1059–1064. https://doi.org/10.15789/1563-0625-RBS-2817.
  16. Weyand CM, Goronzy JJ. The immunology of rheumatoid arthritis. Nat Immunol. 2021;22(1):10–18. https://doi.org/10.1038/s41590-020-00816-x.
  17. Федорова МГ, Комарова ЕВ, Белков АР, Мишин ВА. Аспекты этиологии, патогенеза и морфологии ревматоидного артрита (обзор литературы). Известия высших учебных заведений. Поволжский регион. Медицинские науки. 2024;(2):152–166. https://doi.org/10.21685/2072-3032-2024-2-14.
  18. Liu J, Gao J, Wu Z, Mi L, Li N, Wang Y, et al. Anti-citrullinated Protein Antibody Generation, Pathogenesis, Clinical Application, and Prospects. Front Med (Lausanne). 2022;8:802934. https://doi.org/10.3389/fmed.2021.802934.
  19. Komatsu N, Takayanagi H. Mechanisms of joint destruction in rheumatoid arthritis – immune cell-fibroblast-bone interactions. Nat Rev Rheumatol. 2022;18(7):415–429. https://doi.org/10.1038/s41584-022-00793-5.
  20. Crow MK. Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Ann Rheum Dis. 2023;82(8):999–1014. https://doi.org/10.1136/ard-2022-223741.
  21. Wang X, Wen B, Duan X, Zhang Y, Hu Y, Li H, et al. Recent Advances of Type I Interferon on the Regulation of Immune Cells and the Treatment of Systemic Lupus Erythematosus. J Inflamm Res. 2025;18:4533–4549. doi: 10.2147/JIR.S516195.
  22. Zhu W, He X, Cheng K, Zhang L, Chen D, Wang X, Qiu G, Cao X, Weng X. Ankylosing spondylitis: etiology, pathogenesis, and treatments. Bone Res. 2019;7:22. https://doi.org/10.1038/s41413-019-0057-8.
  23. Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273–2284. https://doi.org/10.1016/S0140-6736(18)30830-4.
  24. Son HH, Moon SJ. Pathogenesis of systemic sclerosis: an integrative review of recent advances. J Rheum Dis. 2025;32(2):89–104. https://doi.org/10.4078/jrd.2024.0129.
  25. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019;381(18):1718–1727. https://doi.org/10.1056/NEJMoa1908681.
  26. Розочкина ЕА, Лукина ГВ, Кольцова ЕН, Лыткина КА, Шмидт ЕИ, Загребнева АИ, Жиляев ЕВ. Сравнительная эффективность генно-инженерных биологических препаратов в реальной клинической практике по данным МЕРА. РМЖ. Медицинское обозрение. 2021;5(2):58–63. https://doi.org/10.32364/2587-6821-2021-5-2-58-63.
  27. Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18. https://doi.org/10.1136/ard-2022-223356.
  28. Kerschbaumer A, Sepriano A, Bergstra SA, Smolen JS, van der Heijde D, Caporali R, et al. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2023;82(1):95–106. https://doi.org/10.1136/ard-2022-223365.
  29. Yu G, Yuan N, Liu D, Nie D, Li H. Recent advances in biologic therapies for ankylosing spondylitis: A 2024 update. Allergol Immunopathol (Madr). 2026;54(1):186–195. https://doi.org/10.15586/aei.v54i1.1542.
  30. Kostopoulou M, Mukhtyar CB, Bertsias G, Boumpas DT, Fanouriakis A. Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations. Ann Rheum Dis. 2024;83(11):1489–1501. https://doi.org/10.1136/ard-2023-225319.